AR069174A1 - Derivados de pirazolo[3,4-b]-piridina inhibidores de proteinquinasas, procesos de preparacion, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades autoinmunes, inflamatorias o proliferativas. - Google Patents
Derivados de pirazolo[3,4-b]-piridina inhibidores de proteinquinasas, procesos de preparacion, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades autoinmunes, inflamatorias o proliferativas.Info
- Publication number
- AR069174A1 AR069174A1 ARP080104815A ARP080104815A AR069174A1 AR 069174 A1 AR069174 A1 AR 069174A1 AR P080104815 A ARP080104815 A AR P080104815A AR P080104815 A ARP080104815 A AR P080104815A AR 069174 A1 AR069174 A1 AR 069174A1
- Authority
- AR
- Argentina
- Prior art keywords
- independently
- halogen
- optionally
- substituted
- alkyl
- Prior art date
Links
- 230000001363 autoimmune Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 11
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 9
- 125000005843 halogen group Chemical group 0.000 abstract 9
- 150000002367 halogens Chemical class 0.000 abstract 9
- 125000001931 aliphatic group Chemical group 0.000 abstract 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 5
- 229920006395 saturated elastomer Polymers 0.000 abstract 5
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 125000001054 5 membered carbocyclic group Chemical group 0.000 abstract 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Reivindicacion 1: Un compuesto representado por la formula estructural (1) o (2), o una de sus sales farmacéuticamente aceptables, en donde: A y A' son, de modo independiente. -N- o -C(R+)-; el anillo B es anillo carbocíclico o heterocíclico saturado de 5 o 6 miembros; R1 es halogeno. -CN, -NO2 o -T1-Q1; T1 está ausente o es un alifático C1-10, en donde una o varias unidades de metileno de T1 están reemplazadas, de manera opcional e independiente, por G; en donde G es -O-. -S(O)p, -N(R')- o -C(O)-; y T1 está sustituido, de manera opcional e independiente, con uno o varios JT1; Q1 está ausente o un anillo monocíclico saturado, parcialmente saturado o completamente insaturado de 3-8 miembros que tiene 0-3 heteroátomos seleccionados, de modo independiente, de los grupos que consisten en O, N y S o un anillo bicíclico saturado, parcialmente saturado o completamente insaturado de 8-12 miembros que tiene 0-5 heteroátomos seleccionados, de modo independiente, del grupo que consiste en O, N, y S, en donde Q1 está sustituidos de manera opcional e independiente, con uno o varios JQ1; en donde, cuando R1 es T1-Q1, entonces T1 y Q1 no están ambos ausentes; R2 es -H. -(CR++2)nCN, -(CR++2)nN(R)2, -(CR++2)nOR, -(CR++2)nC(O)N(R)2 o alifático C1-10 opcionalmente sustituido con uno o varios halogeno, fenilo, OR* o N(R*)2; cada R3 y R4 son, de modo independiente, -H, halogeno, alifático C1-10, heterociclilo, heterociclilalquilo, arilo o aralquilo, en donde R3 y R4 están sustituidos, de manera opcional e independiente, con uno o varios seleccionados del grupo que consiste en alquilo C1-10, halogeno, -CN. -NO2, -N(R*)2. -S(O)pR*, -S(O)pNR*, -C(O)N(R*)2, -NR*C(O), -OC(O)N(R*)2, -N(R*)C(O)OR*, -N(R*)C(O)N(R*)2: y -OR*; o R3 y R4 tomados junto con el carbono al que están unidos, forman C=O o un anillo monocíclico saturado, parcialmente saturado o completamente insaturado de 3-8 miembros que tiene 0-3 heteroátomos seleccionados, de modo independiente, de los grupos que consisten en O, N y S, en donde el anillo está sustituido, de manera opcional e independiente, con uno o varios seleccionados del grupo que consiste en =O, =S, =N-R*, alifático C1-10, haloalifático C1-10, halogeno, -CN, -NO2, -N(R*)2. -S(O)pR*, -S(O)pNR*, -C(O)N(R*)2, -NR*C(O), -OC(O)N(R*)2, -N(R*)C(O)OR*, -N(R*)C(O)N(R*)2: y -OR*; cada R5 y R6, son. de modo independiente. -H, halogeno, haloalifático C1-10 o alifático C1-10, cada R7 es, de modo independiente, haloalifático C1-10, alifático C1-10, halogeno, -NO2, -(CR++2)nCN, -(CR++2)nN(R**)2, -(CR++2)nOR**, o -(CR++2)nC(O)N(R**)2 o dos grupos R7 junto con el carbono al que están unidos, forman C=O; cada JT1 es, de modo independiente, halogeno, -OR^, -N(R^)2 o -CN; cada JQ1 es, de modo independiente, halogeno, alquilo C1-10, haloalquilo C1-10, -ORö, -N(Rö)2, -CN, -NO2. -S(O)pRö, -S(O)pNRö, acilo, carbalcoxialquilo o acetoxialquilo; cada R+ es, de modo independiente, -H, halogeno o alquilo C1-10 sustituido, de manera opcional e independiente, con hasta cinco grupos halogeno; cada R++ es, de modo independiente, -H o halogeno; cada R' es, de modo independiente, -H o alquilo C1-10 sustituido, de manera opcional e independiente, con hasta cinco grupos halogeno; cada R^ es, de modo independiente, -H, alquilo C1-10 o aralquilo, en donde cada R^ está sustituido, de modo opcional e independiente, con hasta cinco grupos halogeno; cada Rö es, de modo independiente, -H, o alquilo C1-10 sustituido, de manera opcional e independiente, con hasta cinco grupos halogeno; cada R es, de modo independiente, -H o alquilo C1-10 sustituido, de manera opcional e independiente, con hasta cinco grupos halogeno; cada R* es, de modo independiente, -H o alquilo C1-10 sustituido, de modo opcional e independiente, con hasta cinco grupos halogeno; cada R**es, de modo independiente, -H o alquilo C1-10 sustituido, de manera opcional e independiente, con hasta cinco grupos halogeno; x es 0 o 1; y es 0, 1 o 2; cada n es, de modo independiente, 0, 1, 2 o 3; y cada p es, de modo independiente, 0, 1 o 2.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98487507P | 2007-11-02 | 2007-11-02 | |
| US4457508P | 2008-04-14 | 2008-04-14 | |
| US10080808P | 2008-09-29 | 2008-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069174A1 true AR069174A1 (es) | 2010-01-06 |
Family
ID=40220120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104815A AR069174A1 (es) | 2007-11-02 | 2008-11-03 | Derivados de pirazolo[3,4-b]-piridina inhibidores de proteinquinasas, procesos de preparacion, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades autoinmunes, inflamatorias o proliferativas. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8173635B2 (es) |
| EP (1) | EP2215089B1 (es) |
| JP (1) | JP5444239B2 (es) |
| KR (1) | KR20100093552A (es) |
| CN (1) | CN101903384A (es) |
| AR (1) | AR069174A1 (es) |
| AU (1) | AU2008331733A1 (es) |
| CA (1) | CA2704266A1 (es) |
| CL (1) | CL2008003280A1 (es) |
| ES (1) | ES2389992T3 (es) |
| IL (1) | IL205458A0 (es) |
| MX (1) | MX2010004819A (es) |
| NZ (1) | NZ585063A (es) |
| TW (1) | TW200924762A (es) |
| WO (1) | WO2009073300A1 (es) |
| ZA (1) | ZA201003050B (es) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3456189B2 (ja) | 2000-03-31 | 2003-10-14 | 日本電気株式会社 | 移動通信システム |
| WO2007084557A2 (en) | 2006-01-17 | 2007-07-26 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of janus kinases |
| CA2673472A1 (en) * | 2006-12-21 | 2008-07-03 | Vertex Pharmaceuticals Incorporated | 5-cyan0-4- (pyrrolo) [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors |
| NZ585063A (en) | 2007-11-02 | 2012-05-25 | Vertex Pharma | [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta |
| JP2011513483A (ja) * | 2008-03-10 | 2011-04-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン |
| US8569337B2 (en) | 2008-07-23 | 2013-10-29 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
| CA2732765A1 (en) * | 2008-08-06 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Aminopyridine kinase inhibitors |
| EP2411352B1 (en) | 2009-03-25 | 2017-01-18 | AbbVie Inc. | Antiviral compounds and uses thereof |
| CN102459259A (zh) * | 2009-05-06 | 2012-05-16 | 沃泰克斯药物股份有限公司 | 吡唑并吡啶类 |
| EA037529B1 (ru) | 2009-06-17 | 2021-04-08 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения соединения для ингибирования репликации вирусов гриппа |
| WO2011094288A1 (en) | 2010-01-27 | 2011-08-04 | Vertex Pharmaceuticals Incorporated | Pyrazolopyrazine kinase inhibitors |
| CN102858769A (zh) * | 2010-01-27 | 2013-01-02 | 沃泰克斯药物股份有限公司 | 吡唑并吡啶激酶抑制剂 |
| CA2787363A1 (en) | 2010-01-27 | 2011-08-04 | Vertex Pharmaceuticals Incorporated | Pyrazolopyrimidine kinase inhibitors |
| CA2787321A1 (en) * | 2010-01-27 | 2011-08-04 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridine kinase inhibitors |
| CN102471342A (zh) * | 2010-05-05 | 2012-05-23 | 沃泰克斯药物股份有限公司 | 用作PKC-θ抑制剂的4取代的吡唑并吡啶类 |
| KR20130128436A (ko) | 2010-12-16 | 2013-11-26 | 버텍스 파마슈티칼스 인코포레이티드 | 인플루엔자 바이러스 복제의 억제제 |
| EP2651938A1 (en) | 2010-12-16 | 2013-10-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| MX2013006836A (es) | 2010-12-16 | 2013-09-26 | Vertex Pharma | Inhibidores de la replicacion de los virus de la influenza. |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| EP2858984A1 (en) | 2012-06-08 | 2015-04-15 | Vertex Pharmaceuticals Inc. | Inhibitors of influenza viruses replication |
| BR112015015890A2 (pt) | 2013-01-30 | 2017-07-11 | Ecolab Usa Inc | sequestrantes de sulfeto de hidrogênio |
| EP3851437A3 (en) | 2013-11-13 | 2021-11-03 | Vertex Pharmaceuticals Incorporated | Methods of preparing 1h-pyrrolo[2,3-b]pyridine derivates |
| ES2741444T3 (es) | 2013-11-13 | 2020-02-11 | Vertex Pharma | Inhibidores de la replicación de virus de la gripe |
| US9556126B2 (en) | 2013-12-20 | 2017-01-31 | Signal Pharmaceuticals, Llc | Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith |
| WO2016004305A2 (en) | 2014-07-02 | 2016-01-07 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| EP3197450A1 (en) * | 2014-09-22 | 2017-08-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of fibrosis |
| DK3286175T3 (da) | 2015-04-22 | 2021-01-04 | Ecolab Usa Inc | Udvikling af højtemperaturstabil scavenger til fjernelse af hydrogensulfid |
| JP6857617B2 (ja) | 2015-05-13 | 2021-04-14 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | インフルエンザウイルスの複製の阻害剤 |
| JP6704416B2 (ja) | 2015-05-13 | 2020-06-03 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | インフルエンザウイルスの複製の阻害剤を調製する方法 |
| US10584286B2 (en) | 2015-09-08 | 2020-03-10 | Ecolab Usa Inc. | Hydrogen sulfide scavengers |
| CA2997083C (en) | 2015-09-08 | 2023-06-13 | Ecolab Usa Inc. | Hydrocarbon soluble/dispersible hemiformals as hydrogen sulfide scavengers |
| CA3031535A1 (en) | 2016-07-29 | 2018-02-01 | Ecolab Usa Inc. | Antifouling and hydrogen sulfide scavenging compositions |
| SI3510033T1 (sl) * | 2016-09-09 | 2022-04-29 | Novartis Ag | Spojine in sestavki kot zaviralci endosomskih toličnih receptorjev |
| EP3652274A1 (en) | 2017-07-13 | 2020-05-20 | Ecolab USA, Inc. | Method of removing a sulfur containing compound by adding a composition |
| BR112021014463A2 (pt) | 2019-01-23 | 2021-09-21 | Championx Usa Inc | Remoção completa de sólidos durante operações sequestrantes de sulfeto de hidrogênio que usam um sequestrante e um aceitador de michael |
| WO2020210508A1 (en) | 2019-04-09 | 2020-10-15 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
| CN111529533B (zh) * | 2020-06-05 | 2021-06-11 | 南华大学附属第一医院 | 溴结构域蛋白4抑制剂jq1或其衍生物在制备治疗脓毒症肠屏障损伤药物中的应用 |
| WO2022234299A1 (en) * | 2021-05-06 | 2022-11-10 | Exscientia Ai Limited | Pkc-theta modulators |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2080531A (en) | 1936-01-08 | 1937-05-18 | United Shoe Machinery Corp | Manufacture of shoes |
| US3314941A (en) | 1964-06-23 | 1967-04-18 | American Cyanamid Co | Novel substituted pyridodiazepins |
| GB1159487A (en) | 1968-04-04 | 1969-07-23 | Standard Telephones Cables Ltd | Capacitors |
| US4988705A (en) | 1985-06-13 | 1991-01-29 | Schering Corporation | Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives |
| JP2890448B2 (ja) | 1988-04-26 | 1999-05-17 | 日産化学工業株式会社 | ピラゾロピリジン系メバロノラクトン類 |
| US5100768A (en) | 1989-05-09 | 1992-03-31 | Kabushiki Kaisha Toshiba | Photosensitive composition |
| JPH03206450A (ja) | 1990-01-09 | 1991-09-09 | Fuji Photo Film Co Ltd | 新規な色素形成カプラー及びそれを用いたハロゲン化銀カラー写真感光材料及びその処理方法 |
| JPH03271289A (ja) | 1990-03-16 | 1991-12-03 | Nissan Chem Ind Ltd | ピラゾロピリジン誘導体の製造法及びジヒドロピラゾロピリジン誘導体 |
| US5338740A (en) | 1993-07-13 | 1994-08-16 | Pfizer Inc. | Angiotensin II receptor antagonists |
| US5646330A (en) | 1995-02-17 | 1997-07-08 | Ciba-Geigy Corporation | Production of enantiomerically enriched ortho-substituted α,α-diaromatic methanols |
| US6194581B1 (en) | 1995-04-07 | 2001-02-27 | Merck & Co., Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| SE9704544D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| US6452008B2 (en) | 1998-02-25 | 2002-09-17 | Sumitomo Pharmaceuticals Company, Limited | Pyridone derivatives and process for preparing the same |
| GB9908410D0 (en) | 1999-04-13 | 1999-06-09 | Pfizer Ltd | Pyridines |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| AR029289A1 (es) | 2000-07-05 | 2003-06-18 | Ishihara Sangyo Kaisha | Derivado de benzoilpiridina o su sal, fungicida que lo contiene como un ingrediente activo, su proceso de produccion e intermediario para producirlo |
| JP2002020386A (ja) | 2000-07-07 | 2002-01-23 | Ono Pharmaceut Co Ltd | ピラゾロピリジン誘導体 |
| DE10035908A1 (de) | 2000-07-21 | 2002-03-07 | Asta Medica Ag | Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel |
| US7179912B2 (en) | 2000-09-01 | 2007-02-20 | Icos Corporation | Materials and methods to potentiate cancer treatment |
| GB0128287D0 (en) | 2001-11-26 | 2002-01-16 | Smithkline Beecham Plc | Novel method and compounds |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| CA2470214A1 (en) * | 2001-12-13 | 2003-06-26 | Abbott Laboratories | 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer |
| DE10222550A1 (de) | 2002-05-17 | 2003-11-27 | Bayer Ag | Substituierte Benzyl-pyrazolopyridine |
| JPWO2004002531A1 (ja) | 2002-06-26 | 2005-10-27 | 小野薬品工業株式会社 | 血管の収縮または拡張による疾患治療剤 |
| WO2004014368A1 (en) | 2002-08-12 | 2004-02-19 | Sugen, Inc. | 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
| WO2004067516A1 (en) * | 2003-01-30 | 2004-08-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta |
| WO2004080463A1 (en) | 2003-03-10 | 2004-09-23 | Schering Corporation | Heterocyclic kinase inhibitors: methods of use and synthesis |
| US20050203067A1 (en) | 2003-05-12 | 2005-09-15 | Hresko Michelle C. | Pesticidal compositions and methods |
| AU2004259755A1 (en) | 2003-07-22 | 2005-02-03 | Janssen Pharmaceutica, N.V. | Quinolinone derivatives as inhibitors of c-fms kinase |
| WO2005044181A2 (en) | 2003-09-09 | 2005-05-19 | Temple University-Of The Commonwealth System Of Higher Education | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors |
| ATE455765T1 (de) | 2003-12-22 | 2010-02-15 | Basilea Pharmaceutica Ag | Aryloxy- und arylthioxyacetophenon-verbindungen zur behandlung von krebs |
| UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| WO2006050076A1 (en) | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| ES2386027T3 (es) * | 2004-10-29 | 2012-08-07 | Abbott Laboratories | Inhibidores de quinasas novedosos |
| WO2006052568A2 (en) | 2004-11-10 | 2006-05-18 | Eli Lilly And Company | Tgf-beta inhibitors |
| DE102004061288A1 (de) * | 2004-12-14 | 2006-06-29 | Schering Ag | 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel |
| PE20061119A1 (es) * | 2005-01-19 | 2006-11-27 | Aventis Pharma Sa | PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie |
| WO2006101456A1 (en) | 2005-03-21 | 2006-09-28 | S*Bio Pte Ltd | Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors |
| JP2008540664A (ja) * | 2005-05-16 | 2008-11-20 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としてのピロロピリジン誘導体 |
| AU2006272951A1 (en) | 2005-05-17 | 2007-02-01 | Plexxikon, Inc. | Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors |
| DE102005035417A1 (de) | 2005-07-28 | 2007-02-01 | Robert Bosch Gmbh | Entfernungsmessgerät und Verfahren zum Befestigen einer elektrooptischen Einheit an einer Leiterträgereinheit |
| US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| DE102005048897A1 (de) | 2005-10-12 | 2007-04-19 | Sanofi-Aventis Deutschland Gmbh | Diacylindazol-derivate als Inhibitoren von Lipasen und Phospholipasen |
| WO2007076423A2 (en) | 2005-12-22 | 2007-07-05 | Smithkline Beecham Corporation | INHIBITORS OF Akt ACTIVITY |
| WO2007084667A2 (en) | 2006-01-19 | 2007-07-26 | Osi Pharmaceutical, Inc. | Fused heterobicyclic kinase inhibitors |
| EP2043655A2 (en) | 2006-04-25 | 2009-04-08 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
| TW200815438A (en) * | 2006-06-13 | 2008-04-01 | Bayer Schering Pharma Ag | Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| KR20140104060A (ko) | 2006-10-19 | 2014-08-27 | 시그날 파마소티칼 엘엘씨 | 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도 |
| JP2008132121A (ja) * | 2006-11-28 | 2008-06-12 | Sanshin Kinzoku Kogyo Kk | 移動ラック装置 |
| CA2672903C (en) | 2006-12-20 | 2012-10-23 | Amgen Inc. | Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer |
| WO2008132121A1 (en) * | 2007-04-26 | 2008-11-06 | Glaxo Group Limited | Lh-indazole-3-amine compounds as ikk1 inhibitors |
| NZ585063A (en) | 2007-11-02 | 2012-05-25 | Vertex Pharma | [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta |
-
2008
- 2008-10-31 NZ NZ585063A patent/NZ585063A/en not_active IP Right Cessation
- 2008-10-31 ES ES08857976T patent/ES2389992T3/es active Active
- 2008-10-31 AU AU2008331733A patent/AU2008331733A1/en not_active Abandoned
- 2008-10-31 TW TW097142239A patent/TW200924762A/zh unknown
- 2008-10-31 US US12/262,459 patent/US8173635B2/en not_active Expired - Fee Related
- 2008-10-31 EP EP08857976A patent/EP2215089B1/en active Active
- 2008-10-31 KR KR1020107012153A patent/KR20100093552A/ko not_active Application Discontinuation
- 2008-10-31 WO PCT/US2008/081933 patent/WO2009073300A1/en active Application Filing
- 2008-10-31 CA CA2704266A patent/CA2704266A1/en not_active Abandoned
- 2008-10-31 JP JP2010532265A patent/JP5444239B2/ja not_active Expired - Fee Related
- 2008-10-31 MX MX2010004819A patent/MX2010004819A/es active IP Right Grant
- 2008-10-31 CN CN2008801218567A patent/CN101903384A/zh active Pending
- 2008-11-03 CL CL2008003280A patent/CL2008003280A1/es unknown
- 2008-11-03 AR ARP080104815A patent/AR069174A1/es unknown
-
2010
- 2010-04-29 IL IL205458A patent/IL205458A0/en unknown
- 2010-04-30 ZA ZA2010/03050A patent/ZA201003050B/en unknown
-
2011
- 2011-10-18 US US13/275,551 patent/US8367697B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20120149680A1 (en) | 2012-06-14 |
| KR20100093552A (ko) | 2010-08-25 |
| CN101903384A (zh) | 2010-12-01 |
| ES2389992T3 (es) | 2012-11-05 |
| EP2215089B1 (en) | 2012-06-27 |
| JP5444239B2 (ja) | 2014-03-19 |
| EP2215089A1 (en) | 2010-08-11 |
| JP2011502994A (ja) | 2011-01-27 |
| MX2010004819A (es) | 2010-07-05 |
| US8173635B2 (en) | 2012-05-08 |
| US20090291937A1 (en) | 2009-11-26 |
| ZA201003050B (en) | 2011-07-27 |
| WO2009073300A1 (en) | 2009-06-11 |
| AU2008331733A1 (en) | 2009-06-11 |
| TW200924762A (en) | 2009-06-16 |
| IL205458A0 (en) | 2010-12-30 |
| NZ585063A (en) | 2012-05-25 |
| CL2008003280A1 (es) | 2010-01-04 |
| US8367697B2 (en) | 2013-02-05 |
| CA2704266A1 (en) | 2009-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR069174A1 (es) | Derivados de pirazolo[3,4-b]-piridina inhibidores de proteinquinasas, procesos de preparacion, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades autoinmunes, inflamatorias o proliferativas. | |
| AR048427A1 (es) | Derivados de sulfonilpirroles con actividad inhibitoria de la histona deacetilasa, composiciones farmaceuticas que los contienen y el uso de las mismas para el tratamiento de enfermedades relacionadas. | |
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| AR103574A1 (es) | Compuestos tricíclicos y usos de lo mismos en medicina | |
| AR058362A1 (es) | Derivados de isoquinolina - aminopirazol su obtencion y su utilizacion como agentes farmaceuticos | |
| AR071823A1 (es) | Derivados heterociclicos de imidazol y pirazol, inhibidores del factor ixa de coagulacion, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diversos trastornos tromboembolicos. | |
| CY1117374T1 (el) | Παραγωγα ιμιδαζοπυριδινης, διαδικασια για την παρασκευη αυτων και θεραπευτικη χρηση αυτων | |
| AR064454A1 (es) | Derivados de pirazol con efecto inhibitorio de fgfr, metodos para su sintesis, composicion farmaceutica que los comprende, un proceso para la preparacion de la misma y su uso en la fabricacion de un medicamento para el tratamiento del cancer. | |
| AR072791A1 (es) | DERIVADOS DE TIAZOLIDIN-2, 4-DIONA, MÉTODOS PARA SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE Y SU USO EN LA ELABORACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER. | |
| AR035371A1 (es) | Aminotiazoles, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento | |
| UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
| AR077328A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| AR079689A1 (es) | Derivados de imidazo[1,2a]piridina, composiciones farmaceuticas que los comprenden y uso de los mismos en trastornos mieloproliferativos, leucemia y enfermedades inmunologicas e inflamatorias. | |
| CO6251243A2 (es) | Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c | |
| AR081848A1 (es) | Inhibidores de la proteina ns5a del vhc | |
| AR032361A1 (es) | Derivados de androstano y sales y solvatos de los mismos, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que comprenden tales compuestos, proceso para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de tales compuestos | |
| AR087348A1 (es) | Indazoles, composiciones farmaceuticas que comprenden tales compuestos y su uso como medicamentos | |
| AR083161A1 (es) | Inhibidores macrociclicos de la replicacion del virus de la hepatitis c, composiciones farmaceuticas que los comprenden, su uso en medicamentos, intermediarios de su sintesis y metodos de preparacion de los mismos | |
| AR073406A1 (es) | Aminodihidrotiazinas fusionadas con tetrahidropiranos,inhibidoras de bace1 y de la produccion de abeta amiloide, composiciones farmaceuticas que las contienen y usos de las mismas para el tratamiento de enfermedades neurodegenerativas,tales como alzheimer. | |
| AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR067156A1 (es) | DERIVADOS DE TETRAHIDRO-2H-PIRIDO(4,3-B)INDOL-2-ILO, UN PROCESO PARA SU PREPARACION, UNA COMPOSICION FARMACEUTICA QUE LOS COMPRENDE Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA INHIBICION DE CATEPSINA K | |
| AR086636A1 (es) | Ligandos sigma utiles para tratar y/o prevenir el dolor asociado a la diabetes tipo 2 y composiciones farmaceuticas que los contienen | |
| AR051753A1 (es) | Metodos para preparar compuestos de indazol | |
| JP2012511588A5 (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |